Physiological Bases for the Superiority of Apolipoprotein B Over Low‐Density Lipoprotein Cholesterol and Non–High‐Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk
Tamara Glavinovic,George Thanassoulis,Jacqueline de Graaf,Patrick Couture,Robert A. Hegele,Allan D. Sniderman
DOI: https://doi.org/10.1161/JAHA.122.025858
2022-10-12
Abstract:In 2019, the European Society of Cardiology/European Atherosclerosis Society stated that apolipoprotein B (apoB) was a more accurate marker of cardiovascular risk than low‐density lipoprotein cholesterol (LDL‐C) and non–high‐density lipoprotein cholesterol. Since then, the evidence has continued to mount in favor of apoB. This review explicates the physiological mechanisms responsible for the superiority of apoB as a marker of the cardiovascular risk attributable to the atherogenic apoB lipoprotein particles chylomicron remnants, very low‐density lipoprotein, and low‐density lipoprotein particles. First, the nature and relative numbers of these different apoB particles will be outlined. This will make clear why low‐density lipoprotein particles are almost always the major determinants of cardiovascular risk and why the concentrations of triglycerides and LDL‐C may obscure this relation. Next, the mechanisms that govern the number of very low‐density lipoprotein and low‐density lipoprotein particles will be outlined because, except for dysbetalipoproteinemia, the total number of apoB particles determines cardiovascular risk, Then, the mechanisms that govern the cholesterol mass within very low‐density lipoprotein and low‐density lipoprotein particles will be reviewed because these are responsible for the discordance between the mass of cholesterol within apoB particles, measured either as LDL‐C or non–high‐density lipoprotein cholesterol, and the number of apoB particles measured as apoB, which creates the superior predictive power of apoB over LDL‐C and non–high‐density lipoprotein cholesterol. Finally, the major apoB dyslipoproteinemias will be briefly outlined. Our objective is to provide a physiological framework for health care givers to understand why apoB is a more accurate marker of cardiovascular risk than LDL‐C or non–high‐density lipoprotein cholesterol. Nonstandard Abbreviations and Acronyms ANGPTL3 angiopoietin like protein 3 CE cholesteryl ester CETP cholesteryl ester transfer protein FH familial hypercholesterolemia Lp(a) lipoprotein(a) PCSK9 proprotein convertase subtilisin kexin 9 Deposition of cholesterol within the arterial wall caused by trapping of apolipoprotein B (apoB)‐containing lipoprotein particles initiates and drives the evolution of atherosclerosis, from the beginning to the end, from the appearance of the first fatty streaks, to the complex, calcified atherosclerotic plaques that cause the clinical events. 1 , 2 However, cholesterol only circulates in plasma within lipoprotein particles, and deposition of cholesterol within the arterial wall only occurs with trapping of apoB particles within the arterial wall. Based on evidence from prospective epidemiological studies, randomized clinical trials, and Mendelian randomization analyses, the 2019 European Society of Cardiology/European Atherosclerosis Society Guidelines concluded that apoB, which measures the number of apoB particles in plasma, is a more accurate marker of the cardiovascular risk attributable to the apoB lipoproteins than low‐density lipoprotein cholesterol (LDL‐C) or non–high‐density lipoprotein cholesterol (non–HDL‐C) and a more accurate index of the adequacy of lipid lowering therapy than LDL‐C or non–HDL‐C. 3 The evidence has grown even stronger since. 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 Moreover, apoB can be measured more accurately by clinical laboratories than LDL‐C or non–HDL‐C, but just as rapidly, and almost as inexpensively, using standardized automated technologies that are available in any modern clinical chemistry laboratory. 12 , 13 Because cholesterol is a major component of all apoB particles, apoB, LDL‐C, and non–HDL‐C are highly correlated. As values of 1 increase, so do values of the 2 others, and so does cardiovascular risk. Conversely, as values of 1 decrease, so do values of the 2 others, and so does cardiovascular risk. However, LDL‐C and non–HDL‐C are not always accurate equivalents of apoB, because the mass of cholesterol per apoB particle varies. 14 , 15 Therefore, at any level of LDL‐C or non–HDL‐C, there is considerable variance in the value of apoB. Similarly, at any level of apoB, there is co -Abstract Truncated-